1.32
10.55%
+0.126
After Hours:
1.40
0.08
+6.06%
ImmunoPrecise Antibodies Ltd stock is currently priced at $1.32, with a 24-hour trading volume of 101.69K.
It has seen a +10.55% increased in the last 24 hours and a -13.16% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.20 pivot point. If it approaches the $1.32 resistance level, significant changes may occur.
Previous Close:
$1.194
Open:
$1.23
24h Volume:
101.69K
Market Cap:
$33.95M
Revenue:
$16.77M
Net Income/Loss:
$-11.87M
P/E Ratio:
-2.1086
EPS:
-0.626
Net Cash Flow:
$-5.90M
1W Performance:
+4.76%
1M Performance:
-13.16%
6M Performance:
-19.51%
1Y Performance:
-54.95%
ImmunoPrecise Antibodies Ltd Stock (IPA) Company Profile
Name
ImmunoPrecise Antibodies Ltd
Sector
Industry
Phone
701 353 0022
Address
4837 Amber Valley Parkway, Suite 11, Fargo
ImmunoPrecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-02-22 | Initiated | H.C. Wainwright | Buy |
Oct-25-21 | Initiated | The Benchmark Company | Buy |
ImmunoPrecise Antibodies Ltd Stock (IPA) Latest News
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
New Strong Buy Stocks for February 7th
Zacks Investment Research
New Strong Buy Stocks for February 5th
Zacks Investment Research
Gold Moves Higher; Campbell Soup Earnings Top Expectations
Benzinga
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
ImmunoPrecise Antibodies Ltd Stock (IPA) Financials Data
ImmunoPrecise Antibodies Ltd (IPA) Revenue 2024
IPA reported a revenue (TTM) of $16.77 million for the quarter ending October 31, 2023, a +8.39% rise year-over-year.
ImmunoPrecise Antibodies Ltd (IPA) Net Income 2024
IPA net income (TTM) was -$11.87 million for the quarter ending October 31, 2023, a +39.11% increase year-over-year.
ImmunoPrecise Antibodies Ltd (IPA) Cash Flow 2024
IPA recorded a free cash flow (TTM) of -$5.90 million for the quarter ending October 31, 2023, a +65.98% increase year-over-year.
ImmunoPrecise Antibodies Ltd (IPA) Earnings per Share 2024
IPA earnings per share (TTM) was -$0.4742 for the quarter ending October 31, 2023, a +44.84% growth year-over-year.
About ImmunoPrecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Cap:
|
Volume (24h):